## Chunk 1 (pages 1-21)

## Key points
- Document/presentation: **“Focused on providers, patients and the bottom line — The B. Braun Portfolio”** (February 23, 2024); presenters: **Bill Miller and Tracy Butryn**; marked **“Rx only”** and **“B. Braun Medical Confidential and Proprietary.”**
- Contract overview highlights:
  - Facility contract numbers: **PP-IV-162, PP-IV-167, PP-IV-172, PP-IV-178, PP-IV-181**
  - **“Full line Supplier”** across **“All Five Contract Categories”**
  - Tiering: **“Acute Tiers Five Tiers”**; **“Non-Acute Tiers Three Ambulatory & Three Infusion Centers Tiers”**
  - Coverage: **“Aggregation Systems/IDNs”**
  - Pricing: **“Firm for 24 Months & 3% Increase Years 3, 4 & 5”**
  - Channel notes: **“Indirect Only for all Disposables”**; **“Capital Direct Only B. Braun Authorized Distributors”**
  - Execution steps: **“Member price activates on agreed upon qualifying tier”**; member signs and submits **LOC** and **PMDF** to B. Braun.
- Product/category scope listed under “Full Line” includes:
  - **Infusion Devices and Dedicated Sets (PP-IV-181)**
  - **Infusion Sets and Accessories (PP-IV-162)**
  - **IV Solutions, Bag-Based Drug Delivery and TPN Macronutrients (PP-IV-167)**
  - **Needleless Connectors (PP-IV-172)**
  - **Pharmacy Compounding Equipment and Admixture Supplies (PP-IV-178)**
  - Also referenced: **Safety IV Catheters (PP-NS-1627; AD-NS-1627; SP-NS-1627)** and **CAPS® 503A and 503B Outsourced Services for IV Admixtures (PP-PH-21BBM0111)**.
- Positioning themes:
  - **“Providers are our purpose”** and solutions aligned to the **“Quintuple Aim”** (Provider Experience, Cost of Care, Patient Experience, Quality and Outcomes, Health Equity).
  - Transition support: **“Simple three-phase process”** and **“Our integration team will work with you at the local and systems level…”**
  - Service model includes **“Dedicated clinical team,” “Dedicated project managers,” “24x7 support,”** and **“One point of contact.”**
- Supply chain / reliability claims:
  - **“$1,000,000,000 investment in North American manufacturing”**
  - **“25 FDA-registered plants for global supply redundancy”**
  - **“Bi-coastal operations”**
  - **“Enhanced safety stock of up to 50 days for supply resiliency of high-use items”**
- Safety/sustainability: states products **“NOT MADE WITH PVC OR DEHP”** (context/details unspecified in the chunk).
- Portfolio overview presented as “Bag to Patient Portfolio” across five areas: infusion devices/sets, IV fluids/drug delivery/TPN macronutrients, pharmacy compounding equipment, infusion sets/accessories, needleless connectors.
- Infusion platform claims:
  - **“Best-in-class industry outcomes for drug library compliance, reduction of alerts and elimination of infusion-related medication errors”**
  - **“deemed best in KLAS”** (no specific ranking/year given).
  - Note: **“Perfusor® PCA Syringe Pump does not offer a wireless option.”**
- Pharmacy products claims (selected):
  - **“Ready-to-use containers designed to decrease pharmacy prep time”**
  - **“Full portfolio of IV Solution bags and irrigation containers not made with natural rubber latex, PVC or DEHP”**
  - **“Single-use PIC containers not made with PVC or DEHP…”**
- Needleless connector positioning: **“designed to minimize risk of infection and needlestick injuries.”**

## Decisions / confirmations
- Contract structure and terms are stated (not explicitly “decided” in text, but presented as defined):
  - Pricing term: **firm 24 months** with **“3% Increase Years 3, 4 & 5”**
  - Channel model: **“Indirect Only for all Disposables”** and **“Capital Direct Only…”**
  - Tiered program: **Acute = five tiers**; **Non-acute = three ambulatory & three infusion center tiers**
- Commitment/rebate framework shown under **“Premier contract commitment”** (specific tier-by-tier requirements not fully visible in provided text).

## Open questions
- What do **LOC** and **PMDF** stand for, and what specific requirements/thresholds determine the **“qualifying tier”**? (unknown)
- Detailed definitions/requirements for each **Acute Care Tier 1–5** and **Non-acute tiers** (unknown; table content appears incomplete in the chunk).
- What is the exact scope of products covered by **“NOT MADE WITH PVC OR DEHP”** claim (which items/categories)? (unknown)
- Details supporting **“deemed best in KLAS”** (year, category, ranking) (unknown).
- Clarification of rebate structure amounts beyond what is visible (unknown).

## Action items (with owners if present)
- **Member**: **“Member signs LOC and PMDF”**
- **Member**: **“Send completed and signed LOC and PMDF to B. Braun”**
- Owner for “integration team” activities is referenced as **“Our integration team”** (B. Braun), but specific tasks/deliverables beyond “work with you…to streamline the transition process” are not detailed (unknown).

## Notable metrics/claims (exact phrases where possible)
- **“Pricing Firm for 24 Months & 3% Increase Years 3, 4 & 5”**
- **“$1,000,000,000 investment in North American manufacturing”**
- **“25 FDA-registered plants for global supply redundancy”**
- **“Enhanced safety stock of up to 50 days for supply resiliency of high-use items”**
- **“Best-in-class industry outcomes for drug library compliance, reduction of alerts and elimination of infusion-related medication errors”**
- **“Our integrated system has been deemed best in KLAS.”**
- **“NOT MADE WITH PVC OR DEHP”**
- Health equity statement: **“B. Braun is committed to addressing inequities in vascular care.”**
